This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murat, A. Articles by Hegi, M. E. Search for Related Content PubMed PubMed Citation Articles by Murat, A. Articles by Hegi, M. E. Social Bookmarking                            What's this?

Stem Cell–Related "Self-Renewal" Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma

Anastasia Murat, Eugenia Migliavacca, Thierry Gorlia, Wanyu L. Lambiv, Tal Shay, Marie-France Hamou, Nicolas de Tribolet, Luca Regli, Wolfgang Wick, Mathilde C.M. Kouwenhoven, Johannes A. Hainfellner, Frank L. Heppner, Pierre-Yves Dietrich, Yitzhak Zimmer, J. Gregory Cairncross, Robert-Charles Janzer, Eytan Domany, Mauro Delorenzi, Roger Stupp, Monika E. Hegi

From the Laboratory of Tumor Biology and Genetics, Centre Universitaire Romand de Neurochirurgie; Division of Neuropathology; Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne; the National Center of Competence in Research Molecular Oncology at the Swiss Institute of Experimental Cancer Research; the Swiss Institute of Bioinformatics, Epalinges; the Centre Universitaire Romand de Neurochirurgie, the Service of Oncology, University Hospital Geneva, Geneva; the Department of Clinical Research and Radiation Oncology, Inselspital and University of Berne, Berne; the Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland; Data Center, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel; the Department of General Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen; Department of Neurooncology, University Clinic Heidelberg, Heidelberg; Institute of Neuropathology, Charité –Universitätsmedizin Berlin, Berlin, Germany; Department of Neurology, Erasmus, Rotterdam, the Netherlands; Institute of Neurology, Medical University of Vienna, Vienna, Austria; and the Department of Clinical Neurosciences, University of Calgary, Calgary, Canada

Corresponding author: Monika E. Hegi, PhD, Laboratory of Tumor Biology and Genetics, Centre Universitaire Romand de Neurochirurgie, Centre Hospitalier Universitaire Vaudois and University of Lausanne, 46, rue du Bugnon, Lausanne 1011/Switzerland; e-mail: Monika.Hegi{at}chuv.ch

Purpose Glioblastomas are notorious for resistance to therapy, which has been attributed to DNA-repair proficiency, a multitude of deregulated molecular pathways, and, more recently, to the particular biologic behavior of tumor stem-like cells. Here, we aimed to identify molecular profiles specific for treatment resistance to the current standard of care of concomitant chemoradiotherapy with the alkylating agent temozolomide.

Patients and Methods Gene expression profiles of 80 glioblastomas were interrogated for associations with resistance to therapy. Patients were treated within clinical trials testing the addition of concomitant and adjuvant temozolomide to radiotherapy.

Results An expression signature dominated by HOX genes, which comprises Prominin-1 (CD133), emerged as a predictor for poor survival in patients treated with concomitant chemoradiotherapy (n = 42; hazard ratio = 2.69; 95% CI, 1.38 to 5.26; P = .004). This association could be validated in an independent data set. Provocatively, the HOX cluster was reminiscent of a "self-renewal" signature (P = .008; Gene Set Enrichment Analysis) recently characterized in a mouse leukemia model. The HOX signature and EGFR expression were independent prognostic factors in multivariate analysis, adjusted for the O-6-methylguanine-DNA methyltransferase (MGMT) methylation status, a known predictive factor for benefit from temozolomide, and age. Better outcome was associated with gene clusters characterizing features of tumor-host interaction including tumor vascularization and cell adhesion, and innate immune response.

Conclusion This study provides first clinical evidence for the implication of a "glioma stem cell" or "self-renewal" phenotype in treatment resistance of glioblastoma. Biologic mechanisms identified here to be relevant for resistance will guide future targeted therapies and respective marker development for individualized treatment and patient selection.

Supported by the Swiss National Science Foundation (Grant No. 3100AO-108266/1; M.E.H.); Jacqueline Seroussi Memorial Foundation for Cancer Research (M.E.H.), Translational Research Fund of the EORTC (M.E.H.); the Nélia and Amadeo Barletta Foundation (M.E.H., R.S.); National Center of Competence in Research (NCCR) Molecular Oncology at the Swiss Institute for Experimental Cancer Research (ISREC) (M.E.H., M.D.); Ridgefield Foundation (E.D.); EC FP6 (E.D.); and the VITAL-IT project of the Swiss Institute of Bioinformatics (E.M., M.D.).

A.M. and E.M. contributed equally to this article.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Felsberg, M. Rapp, S. Loeser, R. Fimmers, W. Stummer, M. Goeppert, H.-J. Steiger, B. Friedensdorf, G. Reifenberger, and M. C. Sabel Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients Clin. Cancer Res., November 1, 2009; 15(21): 6683 - 6693. [Abstract] [Full Text] [PDF]

				H. Colman, L. Zhang, E. P. Sulman, J. M. McDonald, N. L. Shooshtari, A. Rivera, S. Popoff, C. L. Nutt, D. N. Louis, J. G. Cairncross, et al. A multigene predictor of outcome in glioblastoma Neuro Oncology, October 20, 2009; (2009) nop007v1. [Abstract] [Full Text] [PDF]

				B. Neyns, J. Sadones, E. Joosens, F. Bouttens, L. Verbeke, J.-F. Baurain, L. D'Hondt, T. Strauven, C. Chaskis, P. In't Veld, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma Ann. Onc., September 1, 2009; 20(9): 1596 - 1603. [Abstract] [Full Text] [PDF]

				G. Frosina DNA Repair and Resistance of Gliomas to Chemotherapy and Radiotherapy Mol. Cancer Res., July 1, 2009; 7(7): 989 - 999. [Abstract] [Full Text] [PDF]

				W. Zhuang, Z. Qin, and Z. Liang The role of autophagy in sensitizing malignant glioma cells to radiation therapy Acta Biochim Biophys Sin, May 1, 2009; 41(5): 341 - 351. [Abstract] [Full Text] [PDF]

				M. Ropolo, A. Daga, F. Griffero, M. Foresta, G. Casartelli, A. Zunino, A. Poggi, E. Cappelli, G. Zona, R. Spaziante, et al. Comparative Analysis of DNA Repair in Stem and Nonstem Glioma Cell Cultures Mol. Cancer Res., March 1, 2009; 7(3): 383 - 392. [Abstract] [Full Text] [PDF]